Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Birkun (Simferopol, Ukraine). Surfactant-enforced treatment of pseudomonas-induced pneumonia. Eur Respir J 2013; 42: Suppl. 57, 734

Member's Comments

No comment yet.

Related content which might interest you: Development of an antibody therapy for the treatment of pneumonia Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Modern etiology of severe community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP) Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Factors affecting treatment success in community acquired pneumonia (CAP) Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Clinical impact of a prediction score for drug-resistance in community-onset pneumonia Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Common organisms causing community acquired pneumonia Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013 Drug-resistant pathogens prediction scores in CAP, HCAP and immunocompromised Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Clinical characteristics of 11 cases of pulmonary abscess in children Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 30 day mortality and eosinopenia in patients with pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 Multiple tension pneumatocele due to necrotising pneumonia Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia? Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Should empyema be managed differently in case of necrotizing pneumonia? Source: Annual Congress 2013 –Pulmonary infection in children: diagnosis and long-term effects Year: 2013 Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP) Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 COPD and pneumonia Source: International Congress 2015 – Different data in COPD Year: 2015 Bacteraemia in outpatient with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Colistin therapy for nosocomial pneumonia and nephrotoxicity Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013